Get the Daily Brief
Latest Biotech News
IL‑12 Nanoparticles Eradicate Metastatic Ovarian Tumors in Mice
MIT researchers reported in Nature Materials that polymer‑coated nanoparticles delivering IL‑12 directly to ovarian tumors, when combined with immune checkpoint inhibitors, eliminated metastatic...
Myeloid IFNγ Signaling Identified as Checkpoint Resistance Lever in Kidney Cancer
Dana‑Farber investigators described a mechanism of resistance to immune checkpoint inhibitors in renal cell carcinoma driven by interferon‑gamma signaling within tumor‑associated myeloid cells....
Pfizer moves to enforce Metsera deal – Delaware court fight begins
Pfizer filed suit in Delaware against Metsera and Novo Nordisk, alleging breach of a September merger agreement and seeking to block Metsera from terminating the Pfizer buyout while Novo pursues a...
FDA halts Intellia CRISPR trials – liver safety probe
The U.S. Food and Drug Administration has placed clinical holds on Intellia’s Phase 3 studies of nexiguran ziclumeran (nex‑z), a CRISPR‑based gene editing therapy for transthyretin amyloidosis,...
Gene therapy achieves 95% success in ADA‑SCID follow‑up – UCL and UCLA
A joint UCL–UCLA team reported multi‑year follow‑up showing a gene therapy approach restored immune function in 95% of treated children with ADA‑SCID, with no serious long‑term safety signals...
Porcine kidneys infused with human organoids...first scalable transplant tests
Researchers demonstrated a scalable workflow to generate thousands of human kidney organoids and integrate them into porcine kidneys during ex vivo normothermic perfusion. Teams at the Institute...
Thermo Fisher agrees to buy Clario for $8.88 billion – data and endpoints play
Thermo Fisher Scientific announced a definitive agreement to acquire Clario Holdings for $8.88 billion in cash to expand its clinical‑trial data and endpoint services. The deal aims to combine...
Moderna’s post‑vaccine pivot falters – restructuring and lost contracts
Moderna is facing a deep strategic inflection as Covid‑vaccine sales wane and promised mRNA pipeline successes have yet to materialize. The company has cut costs, disclosed layoffs and...
AI models push binding‑affinity prediction — Boltz‑2 and physics‑grounded LQMs
Researchers and industry teams reported advances in AI‑driven drug discovery, including open‑source models such as Boltz‑2 and physics‑informed large quantitative models (LQMs) that significantly...
IL‑12‑releasing nanoparticles enable durable ovarian tumor clearance with checkpoint inhibitors
MIT researchers reported polymer‑coated nanoparticles that deliver IL‑12 directly to ovarian tumors, markedly enhancing responses to immune checkpoint inhibitors in mouse models. Preclinical data...
Ultra‑broad hybrid capture NGS detects circulating pathogen DNA in plasma
A team published a hybrid capture–based targeted NGS approach that amplifies detection of circulating microbial cell‑free DNA in blood plasma, enabling broader pathogen discovery and potential...
FDA signals deregulation push — agency guidance and bespoke gene‑therapy pathway guidance emerge
FDA Commissioner remarks signaled an intent to pursue further 'deregulatory' initiatives following recent relaxations in biosimilar trial requirements, indicating a regulatory tone favoring...
Pfizer sues to block Metsera sale—Novo bid triggers courtroom fight
Pfizer filed suit in the Delaware Court of Chancery seeking to enforce its $4.9 billion merger agreement with obesity biotech Metsera and to block an unsolicited rival offer from Novo Nordisk....
FDA places Intellia CRISPR trials on hold: liver safety probe
The FDA imposed a clinical hold on two Phase 3 studies of Intellia’s CRISPR gene‑editing therapy nexiguran ziclumeran (nex‑z) following reports of liver complications. The hold covers trials in...
Moderna retreats: cuts, canceled contracts and a pivot after Covid boom
Moderna reported shrinking Covid vaccine revenues, workforce reductions and tightened spending as federal contracts were canceled and product expectations cooled. The company lost a $766 million...
Gene therapy ‘cure’ for ADA‑SCID posts 95% success—UCL, UCLA follow‑up
A joint UCL‑UCLA research initiative reported multi‑year follow‑up showing their gene therapy for ADA‑SCID restored immune function in roughly 95% of treated children with no serious long‑term...
Scalable human kidney organoids integrated with porcine kidneys—transplant step
Researchers published a Nature Biomedical Engineering study demonstrating a scalable method to produce thousands of human kidney organoids and to integrate them into perfused porcine kidneys ex...
IL‑12 nanoparticles plus checkpoint inhibitors wipe out ovarian metastases in mice
MIT and collaborators reported in Nature Materials that polymer‑coated nanoparticles engineered to deliver IL‑12 directly to ovarian tumor sites produced durable antitumor immunity when combined...
Patent cliff looms—Biopharma M&A surges as companies chase new revenues
Industry analysis found approximately $230 billion in annual sales tied to top blockbusters facing patent expirations through 2029, triggering accelerated M&A and portfolio reshaping across big...
Engineered Cas9 and Baby KJ pathway: lab fixes meet regulatory playbook
A University of California Berkeley team reported a protein engineering strategy that increases Cas9 nuclear import by inserting additional nuclear localization signals into surface loops,...